###begin article-title 0
###xml 30 38 <span type="species:ncbi:9606">patients</span>
Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN </italic>
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 184 190 184 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 108 116 <span type="species:ncbi:9606">patients</span>
Mutations in the genes PRKN and LRRK2 are the most frequent known genetic lesions among Parkinson's disease patients. We have previously reported that in the Portuguese population the LRRK2 c.6055G > A; p.G2019S mutation has one of the highest frequencies in Europe.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2</italic>
###xml 72 83 72 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN, SNCA </italic>
###xml 87 93 87 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PINK1 </italic>
###xml 519 523 519 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNCA</italic>
###xml 525 530 525 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN </italic>
###xml 534 540 534 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PINK1 </italic>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
###xml 208 216 <span type="species:ncbi:9606">patients</span>
###xml 259 267 <span type="species:ncbi:9606">patients</span>
###xml 330 338 <span type="species:ncbi:9606">patients</span>
###xml 383 391 <span type="species:ncbi:9606">patients</span>
Here, we follow up on those results, screening not only LRRK2, but also PRKN, SNCA and PINK1 in a cohort of early-onset and late-onset familial Portuguese Parkinson disease patients. This series comprises 66 patients selected from a consecutive series of 132 patients. This selection was made in order to include only early onset patients (age at onset below 50 years) or late-onset patients with a positive family history (at least one affected relative). All genes were sequenced bi-directionally, and, additionally, SNCA, PRKN and PINK1 were subjected to gene dosage analysis.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN</italic>
###xml 197 201 197 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN</italic>
###xml 226 231 226 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2</italic>
###xml 112 120 <span type="species:ncbi:9606">patients</span>
We found mutations both in LRRK2 and PRKN, while the remaining genes yielded no mutations. Seven of the studied patients showed pathogenic mutations, in homozygosity or compound heterozygosity for PRKN, and heterozygosity for LRRK2.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 35 43 <span type="species:ncbi:9606">patients</span>
###xml 195 203 <span type="species:ncbi:9606">patients</span>
Mutations are common in Portuguese patients with Parkinson's disease, and these results clearly have implications not only for the genetic diagnosis, but also for the genetic counseling of these patients.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 122 123 122 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 413 414 413 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 415 416 415 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 440 445 440 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNCA </italic>
###xml 477 482 477 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN </italic>
###xml 504 508 504 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DJ1 </italic>
###xml 536 542 536 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PINK1 </italic>
###xml 591 597 591 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 688 689 688 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 690 691 690 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
Parkinson's disease (PD) is clinically characterized by resting tremor, rigidity, bradykinesia, and postural instability [1]. The gold standard of PD diagnosis remains a pathological one. Pathological hallmarks include cell loss in pigmented nuclei and the formation of eosinophilic intra-cytoplasmic inclusions, termed Lewy bodies, particularly in the dopaminergic neurons of the substantia nigra pars compacta [2,3]. So far, mutations in SNCA (Alpha-synuclein; OMIM#163890), PRKN (Parkin OMIM#602544), DJ1 (Oncogene DJ1 OMIM#602533), PINK1 (PTEN-Induced Putative Kinase 1 OMIM#608309) and LRRK2 (Leucine-Rich Repeat Kinase 2 OMIM#609007) have been implicated as causes of monogenic PD [4-9].
###end p 11
###begin p 12
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNCA </italic>
###xml 115 116 115 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 219 224 219 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN </italic>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 295 296 295 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 320 335 320 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PINK1 and DJ-1 </italic>
###xml 479 481 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 509 515 509 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 588 594 588 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 839 841 839 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 842 844 842 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
A missense mutation within SNCA encoding the protein alpha-synuclein was the first identified genetic cause of PD [6] and copy number mutations at this locus have also been shown to cause familial PD [10]. Mutations in PRKN are a common cause of autosomal recessive early-onset parkinsonism [11,7], however mutations in PINK1 and DJ-1 have also been reported as associated with this type of parkinsonism, although only five causative mutations have been described in the latter [12-14]. Mutations in the gene LRRK2 are a common cause of autosomal dominant and apparently sporadic PD. The LRRK2 mutation c.6055G > A; p.G2019S, accounts for 1-2% of typical sporadic PD in the North American and Northern European white population, with higher prevalence in Portuguese (6%), Ashkenazi Jewish (18.3%) and North African Arab populations (39%) [15-18].
###end p 12
###begin p 13
###xml 67 73 67 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 171 176 171 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2</italic>
###xml 178 182 178 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNCA</italic>
###xml 184 189 184 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN </italic>
###xml 193 199 193 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PINK1 </italic>
###xml 100 108 <span type="species:ncbi:9606">patients</span>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
We had previously shown that the c.6055G > A; p.G2019S mutation in LRRK2 is common in Portuguese PD patients [15]. Here we extend upon this study to search for additional LRRK2, SNCA, PRKN and PINK1 mutations in a clinic-based cohort of patients, mainly from the central region of Portugal.
###end p 13
###begin title 14
Methods
###end title 14
###begin p 15
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 783 785 783 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1139 1145 1139 1145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 1463 1464 1463 1464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 41 49 <span type="species:ncbi:9606">patients</span>
###xml 446 454 <span type="species:ncbi:9606">patients</span>
###xml 636 644 <span type="species:ncbi:9606">patients</span>
###xml 773 781 <span type="species:ncbi:9606">patients</span>
###xml 851 859 <span type="species:ncbi:9606">patients</span>
###xml 1004 1012 <span type="species:ncbi:9606">patients</span>
###xml 1228 1236 <span type="species:ncbi:9606">patients</span>
###xml 1273 1281 <span type="species:ncbi:9606">patients</span>
###xml 1306 1314 <span type="species:ncbi:9606">patients</span>
###xml 1414 1422 <span type="species:ncbi:9606">patients</span>
After obtaining informed consent, 132 PD patients underwent a standardized neurological examination by a movement disorder specialist. The diagnosis of PD was based on the UK Brain Bank diagnostic criteria (family history was not used as an exclusion criterion) and those published by Gelb et. al. [2,19]. Family history was considered positive if parkinsonism was reported in at least a first- or second-degree relative. Collection of these 132 patients was performed at the Movement Disorder Clinics of both the University of Coimbra Hospital and the Lisbon Hospital Center - Center Region EPE in Lisbon, in a consecutive manner, all patients consent to participate. This cohort is identical to that previously described by us except for the inclusion of 4 additional PD patients [15]. From this series of 132 subjects we have selected 66 unrelated patients to include only those with a positive family history for parkinsonism, or early-onset disease (age at onset <50 years of age). The remaining 66 patients failed to meet either of these criteria, were related to a proband already included or had previously been found to carry the LRRK2 c.6055G > A; p.G2019S mutation (n = 11). This selection led to the inclusion of 39 patients with positive family history and 46 patients with early-onset PD; 19 patients presented with both an early-onset phenotype and a positive family history, thus the net number of patients from both inclusion groups is 66 (Table 1).
###end p 15
###begin p 16
###xml 12 20 <span type="species:ncbi:9606">patients</span>
Features of patients studied, where more than one affected member was identified in a family only the presenting affected member (proband) is included.
###end p 16
###begin p 17
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 182 190 <span type="species:ncbi:9606">patients</span>
###xml 433 441 <span type="species:ncbi:9606">patients</span>
###xml 488 496 <span type="species:ncbi:9606">patients</span>
Additionally we have included a control group comprised of 126 healthy subjects as previously described [15]. Briefly, this control group consisted primarily of spouses accompanying patients to the clinic (~80%); the remaining controls were recruited from non-neurology outpatient clinics, after observation by the movement disorders specialist. This series presented a mean age of 60.5 +/- 23.1 years. Apart from the spouses of the patients, no other familiarity with movement disorders patients was found. All individuals are Caucasian and of apparent Portuguese ancestry.
###end p 17
###begin p 18
###xml 94 98 94 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNCA</italic>
###xml 100 104 100 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN</italic>
###xml 106 112 106 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PINK1 </italic>
###xml 116 122 116 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 171 176 171 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2</italic>
###xml 248 253 248 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN </italic>
Genomic DNA was extracted from peripheral blood using standard methods. We screened the genes SNCA, PRKN, PINK1 and LRRK2 for sequence variants and, with the exception of LRRK2, for genomic copy number variants. The reference sequence used for the PRKN gene throughout this paper is based on the accession number NM_004562 and codon counting starts from the first ATG.
###end p 18
###begin p 19
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNCA</italic>
###xml 10 15 10 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN </italic>
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PINK1</italic>
###xml 228 229 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 252 258 252 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 344 346 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
For SNCA, PRKN and PINK1, all exons were polymerase chain reaction-amplified and sequenced in both directions using BigDye chemistry (Applied Biosystems, Foster City, CA) on an ABI 3100 Genetic Analyzer as previously described [7,20,21]. While for the LRRK2 gene, only exon 41 was screened for mutations, using conditions previously described [15].
###end p 19
###begin p 20
###xml 109 114 109 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN </italic>
###xml 135 139 135 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNCA</italic>
###xml 182 188 182 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PINK1 </italic>
###xml 501 503 498 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 676 679 659 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct </italic>
###xml 665 679 656 662 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;&#916;<italic>Ct </italic></sup>
Gene dosage analysis was performed using the ABI 7900 Sequence Detection System. Exons 1,2, 4-9 and 11-12 of PRKN and exons 1 and 2 of SNCA, as well as the complete coding region of PINK1 were individually co-amplified with beta-globin, which served as an endogenous reference gene. Each plate contained six replicates of every genomic DNA sample, control DNA, and a no-template water control. The cycle in the log phase of PCR amplification at which a significant fluorescence threshold was reached (Ct) was used to quantify each exon relative to beta-globin. The dosage of each exon relative to beta-globin and normalized to control DNA was determined using the 2-DeltaDeltaCt method (Applied Biosystems, Foster City, CA).
###end p 20
###begin title 21
Results
###end title 21
###begin p 22
###xml 154 155 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 236 237 236 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1145 1146 1145 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
###xml 312 320 <span type="species:ncbi:9606">patients</span>
###xml 459 466 <span type="species:ncbi:9606">patient</span>
Analysis of both sequence and copy number yielded several parkin mutations in our subset of patients. The positive results found are represented in Table 2, and the electropherograms corresponding to point mutations are shown in Figure 1. We found four patients in whom both alleles were mutated; three of these patients had the same homozygous mutation (c.154delA; p.N52fsX80), a single base pair deletion that inserts a premature stop codon downstream; one patient showed deletion of exon 2 and duplication of exon 5; analysis of a sixth sample (S4) showed data consistent with a homozygous c.1183G > T; p.E395X mutation and a duplication of exon 9; because the co-occurrence of 3 mutations in the same gene is unlikely we designed an additional forward primer that flanked the E395X mutation as close as possible on the 5' side; sequencing of the PCR product generated by amplification with this new primer and primer PRKNexon11R showed the E395X in a heterozygote state, suggesting that the duplication of exon 9 (and presumably exon 10, which we were unable to assay) interfered with the original PCR and sequencing reaction. Thus in Table 2 this mutation is denoted as a compound heterozygous E395X/exon 9 duplication mutation.
###end p 22
###begin p 23
###xml 0 57 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Electropherograms of the pathogenic point mutations found</bold>
###xml 168 173 168 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN </italic>
###xml 277 282 277 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN </italic>
###xml 419 425 419 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 525 530 525 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN </italic>
Electropherograms of the pathogenic point mutations found. image of the four pathogenic variants discovered in our series. A) chromatogram of the homozygous 154delA in PRKN exon 2, predicted to cause the N52fsX80 aminoacid change; B) chromatogram of the new mutation G1183T in PRKN exon 11, apparently homozygous, predicted to cause a premature stop codon at position 395; C) chromatogram of the heterozygous G6055A in LRRK2 exon 41, predicted to cause the G2019S change; D) chromatogram of the heterozygous C719T variant in PRKN exon 6, predicted to cause the T240M change.
###end p 23
###begin p 24
Variants found
###end p 24
###begin p 25
###xml 76 78 76 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink"># </sup>
Homo: Homozygosity; Het: heterozygosity; * previously undescribed mutation; # Variants of unknown significance e.g pathogenicity not confirmed herein. AAO: Age at onset.
###end p 25
###begin p 26
###xml 36 42 36 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 173 178 173 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN </italic>
Two samples tested positive for the LRRK2 c.6055G > A; p.G2019S mutation, sample S12 and sample S7. Notably, analysis of sample S7 also showed a heterozygous duplication of PRKN exon 9. Screening of variants E395X, G2019S and 154delA in 252 control chromosomes failed to reveal any control subjects harboring these mutations.
###end p 26
###begin p 27
###xml 79 83 79 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN</italic>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 231 238 <span type="species:ncbi:9606">patient</span>
Additionally, we have identified three patients with heterozygous mutations in PRKN: one harboring the T240M variant; another with a deletion of exons 8 through 11 and one with an exon 8 duplication. Furthermore, we have found one patient with two heterozygous dosage variants: an exon 2 deletion and an exon 5 duplication.
###end p 27
###begin p 28
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNCA </italic>
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PINK1</italic>
No mutations were found in SNCA or PINK1.
###end p 28
###begin title 29
Discussion
###end title 29
###begin p 30
###xml 57 61 57 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN</italic>
###xml 63 75 63 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PINK1, SNCA </italic>
###xml 79 84 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2</italic>
###xml 393 399 391 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 402 406 400 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN</italic>
###xml 106 114 <span type="species:ncbi:9606">patients</span>
###xml 463 471 <span type="species:ncbi:9606">patients</span>
We present in this study a detailed mutation analysis of PRKN, PINK1, SNCA and LRRK2. We have included PD patients with a positive family history (n = 19 age at onset <50 years, n = 20 age at onset >/= 50 years), or early-onset sporadic disease (n = 27) in order to maximize our chances of identifying mutations. This approach has led us to find 6 subjects (9.1%) with pathogenic mutations in LRRK2 or PRKN, in addition to 4 variants of unknown significance in 4 patients.
###end p 30
###begin p 31
###xml 24 26 24 26 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 387 392 387 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN </italic>
###xml 476 478 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 558 564 558 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 228 236 <span type="species:ncbi:9606">patients</span>
###xml 486 493 <span type="species:ncbi:9606">patient</span>
###xml 564 571 <span type="species:ncbi:9606">patient</span>
###xml 794 802 <span type="species:ncbi:9606">patients</span>
###xml 840 848 <span type="species:ncbi:9606">patients</span>
###xml 947 955 <span type="species:ncbi:9606">patients</span>
In our previous report [15] we showed that the c.6055G > A; p.G2019S LRRK2 mutation underlies about 6% of late-onset PD in the Portuguese population. While we did not find any c.6055G > A; p.G2019S carriers in the 20 late-onset patients studied here, we did identify c.6055G > A; p.G2019S in 2 of 46 early-onset cases. One of these individuals also carried a heterozygous duplication of PRKN exon 9 consistent with the notion of digenic parkinsonism, as previously described [22]. This patient presented no family history consistent with PD, while the other LRRK2 patient had positive family history. Taking into account the removal of samples previously found to carry the c.6055G > A; p.G2019S mutation we calculate that this mutation is present in 9 probands out of the entire series of 132 patients; this represents 2 of 46 early-onset patients, counting only sporadic cases and a single proband from each family (4.3%) and 7 of 76 late-onset patients counting only sporadic cases and a single proband from each family (9.2%).
###end p 31
###begin p 32
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN </italic>
###xml 170 174 170 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN</italic>
###xml 467 472 467 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN </italic>
###xml 751 752 751 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 805 814 805 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in trans </italic>
###xml 1195 1204 1195 1204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in trans </italic>
###xml 1306 1311 1306 1311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN </italic>
###xml 1660 1664 1660 1664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN</italic>
###xml 247 255 <span type="species:ncbi:9606">patients</span>
###xml 302 310 <span type="species:ncbi:9606">patients</span>
###xml 491 498 <span type="species:ncbi:9606">patient</span>
###xml 730 737 <span type="species:ncbi:9606">patient</span>
###xml 989 996 <span type="species:ncbi:9606">patient</span>
###xml 1362 1369 <span type="species:ncbi:9606">patient</span>
###xml 1578 1586 <span type="species:ncbi:9606">patients</span>
###xml 1724 1731 <span type="species:ncbi:9606">patient</span>
We found several PRKN mutations as either homozygous or compound heterozygous loss of function changes. The N52fsX80 variant was the most frequent mutation identified in PRKN. It was present as a homozygous mutation in three unrelated young onset patients (of 46, 6.5%). Analysis of relatives of these patients failed to show any heterozygous carriers of this mutation with parkinsonism. We identified a heterozygous deletion of exon 2 and a duplication of exon 5 in PRKN in one early-onset patient with positive family history. The only affected family member that was available for testing was the sibling of S10 who presented with the same two variants, albeit with a remarkably different age at onset (50 years vs 35 years of patient S10) (Figure 2). While parsimony suggests that these mutations are in trans we were unable to unequivocally establish phase as DNA was unavailable from other family members. We also identified a heterozygous deletion of exons 8 through 11 in a female patient with an age at onset of 32 years. Additional family members were unavailable, so we were unable to determine whether this mutation represented a single contiguous mutation or two mutations existing in trans and thus the pathogenicity of the observed changes remains unknown. We identified a novel mutation in PRKN exon 11 (E395X) as a heterozygous alteration. This patient also possessed a heterozygous duplication of exon 9. The pathogeneicity of the new E395X mutation is clear since it is a nonsense mutation that occurs upstream of a functional domain of the protein. Of these patients presenting either homozygous or clear compound heterozygous mutations in PRKN, four (80%) have an age at onset below 40 years. Only one (patient S4) presents late-onset disease (53 years).
###end p 32
###begin p 33
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Dosage plots</bold>
Dosage plots. Dosage plot of the variants found in PRKN in sample S10 and its sibling here denoted as S9. Represented are exons 1, 2, 4-9, 11 and 12. Each exon was compared with the beta-globin gene and normalized to a control DNA.
###end p 33
###begin p 34
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN </italic>
###xml 249 254 249 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN </italic>
###xml 197 205 <span type="species:ncbi:9606">patients</span>
###xml 339 347 <span type="species:ncbi:9606">patients</span>
In addition we identified several PRKN variants of unknown significance. The T240M alteration, an exon 8 deletion and an exon 8 duplication were each identified as heterozygous mutations in single patients. In the absence of additional mutations in PRKN in these subjects, we have not considered these as disease causing variants in these patients. We make this statement with caution, since we cannot rule out copy number mutations in exons 3 or 10, which we were unable to assay effectively.
###end p 34
###begin title 35
Conclusion
###end title 35
###begin p 36
###xml 359 364 359 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN </italic>
###xml 409 415 409 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PINK1 </italic>
###xml 419 424 419 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNCA </italic>
###xml 481 483 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 843 848 843 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKN </italic>
It is now clear that genetics plays an important role in the pathogenesis of PD. Specifically, in the Portuguese population, we have found a reasonable number of mutations: the frequency of the c.6055G > A; p.G2019S is one of the highest in Europe, and in the present paper we have found that 8.7% (4 out of 46 cases) of early-onset cases are attributable to PRKN mutations. Similar to other reports we found PINK1 and SNCA mutations to be a rare cause of disease in our families [23]. Taken as a whole these results have implications mainly for clinicians in Portugal; in particular showing that genetic screening may aid the diagnosis of PD in this population. However, even with the combination of gene dosage and sequencing, a significant proportion of mutations might remain undetected, probably due to the size and the complexity of the PRKN gene. In this way, negative results should be interpreted with caution, as well as heterozygous mutations in this gene.
###end p 36
###begin title 37
Competing interests
###end title 37
###begin p 38
The author(s) declare that they have no competing interests.
###end p 38
###begin title 39
Authors' contributions
###end title 39
###begin p 40
JMB and RJG performed the genotyping, and drafted the manuscript. MHR, CJ, AM, MD, AC and CS contributed to collecting materials. CRO, JH, and AS participated in the study design and coordination, together with drafting the manuscript. All authors read and approved the final manuscript.
###end p 40
###begin title 41
Pre-publication history
###end title 41
###begin p 42
The pre-publication history for this paper can be accessed here:
###end p 42
###begin p 43

###end p 43
###begin title 44
Acknowledgements
###end title 44
###begin p 45
###xml 13 21 <span type="species:ncbi:9606">patients</span>
###xml 206 211 <span type="species:ncbi:9606">Human</span>
We thank the patients for taking part in this research. This work was supported in part by the Intramural program of the National Institute on Aging, National Institutes of Health, Department of Health and Human Services and FCT grants (SFRH/BD/29647/2006) and (SFRH/BD/27442/2006).
###end p 45
###begin article-title 46
Parkinson's disease: mechanisms and models
###end article-title 46
###begin article-title 47
Accuracy of the clinical diagnosis of idiopathic Parkinson's disease: A clinicapathological study of 100 cases
###end article-title 47
###begin article-title 48
Genetics of parkinsonism
###end article-title 48
###begin article-title 49
Hereditary early-onset Parkinson's disease caused by mutations in PINK1
###end article-title 49
###begin article-title 50
Localization of autosomal recessive early-onset parkinsonism to chromosome 1p36 (PARK7) in an independent dataset
###end article-title 50
###begin article-title 51
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease
###end article-title 51
###begin article-title 52
Mutations in the parkin gene cause autossomal recessive juvenile parkinsonism
###end article-title 52
###begin article-title 53
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease
###end article-title 53
###begin article-title 54
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology
###end article-title 54
###begin article-title 55
alpha-Synuclein locus triplication causes Parkinson's disease
###end article-title 55
###begin article-title 56
DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease
###end article-title 56
###begin article-title 57
The role of pathogenic DJ-1 mutations in Parkinson's disease
###end article-title 57
###begin article-title 58
Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism
###end article-title 58
###begin article-title 59
Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7)
###end article-title 59
###begin article-title 60
G2019S Dardarin Substitution is a Common Cause of Parkinson's Disease in a Portuguese Cohort
###end article-title 60
###begin article-title 61
Genetics of Parkinson's disease: LRRK2 on the rise
###end article-title 61
###begin article-title 62
LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs
###end article-title 62
###begin article-title 63
LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews
###end article-title 63
###begin article-title 64
Diagnostic criteria for Parkinson disease
###end article-title 64
###begin article-title 65
###xml 92 100 <span type="species:ncbi:9606">patients</span>
Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients
###end article-title 65
###begin article-title 66
Novel PINK1 mutations in early-onset parkinsonism
###end article-title 66
###begin article-title 67
Digenic parkinsonism: investigation of the synergistic effects of PRKN and LRRK2
###end article-title 67
###begin article-title 68
Understanding the molecular causes of Parkinson's disease
###end article-title 68

